Payment overview · 2025
General Payments
$513.78
24 reported records · 8 companies
Healthcare provider profile · identity verified
Anthony W Shallin, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GEORGETOWN, TX · NPI 1891734968
Verified facts
What the public records show
CMS Open Payments records show Anthony W Shallin, M.D. received $513.78 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 21.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $110.33 | 21.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.86 | 21.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.58 | 16.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.16 | 12.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.75 | 11.4% | 3 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $47.14 | 9.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.51 | 4.4% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.45 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.78 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.86 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.86 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $85.58 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $81.19 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.54 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.51 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.11 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 62 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
54 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 691 | 189 |
| Levothyroxine Sodium | Levothyroxine Sodium | 668 | 165 |
| Losartan Potassium | Losartan Potassium | 507 | 139 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 122 |
| Pravastatin Sodium | Pravastatin Sodium | 400 | 111 |
| Omeprazole | Omeprazole | 390 | 111 |
| Simvastatin | Simvastatin | 362 | 98 |
| Lisinopril | Lisinopril | 328 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 212 | 69 |
| Fluticasone Propionate | Fluticasone Propionate | 196 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 54 |
| Metformin Hcl | Metformin Hcl | 187 | 52 |
| Gabapentin | Gabapentin | 182 | 60 |
| Finasteride | Finasteride | 178 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 50 |
| Tramadol Hcl | Tramadol Hcl | 172 | 58 |
| Allopurinol | Allopurinol | 171 | 49 |
| Glimepiride | Glimepiride | 161 | 47 |
| Montelukast Sodium | Montelukast Sodium | 151 | 38 |
| Ezetimibe | Ezetimibe | 141 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 41 |
| Trazodone Hcl | Trazodone Hcl | 137 | 49 |
| Metformin Hcl Er | Metformin Hcl | 135 | 41 |
| Sertraline Hcl | Sertraline Hcl | 135 | 39 |
| Meloxicam | Meloxicam | 134 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 128 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 38 |
| Furosemide | Furosemide | 118 | 41 |
| Synthroid | Levothyroxine Sodium | 117 | 33 |
| Alprazolam | Alprazolam | 114 | 32 |
| Amoxicillin | Amoxicillin | 113 | 84 |
| Azelastine Hcl | Azelastine Hcl | 111 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 35 |
| Donepezil Hcl | Donepezil Hcl | 90 | 24 |
| Spironolactone | Spironolactone | 89 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 84 | 28 |
| Potassium Chloride | Potassium Chloride | 83 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 23 |
| Estradiol | Estradiol | 80 | 30 |
| Buspirone Hcl | Buspirone Hcl | 79 | 26 |
| Atenolol | Atenolol | 76 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 57 |
| Lovastatin | Lovastatin | 65 | 17 |
| Alendronate Sodium | Alendronate Sodium | 63 | 20 |
| Eliquis | Apixaban | 62 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 57 | 25 |
| Paxlovid | Nirmatrelvir/Ritonavir | 54 | 53 |
| Clonazepam | Clonazepam | 53 | 18 |
| Celecoxib | Celecoxib | 51 | 18 |
| Azithromycin | Azithromycin | 50 | 41 |
| Temazepam | Temazepam | 48 | suppressed |
| Famotidine | Famotidine | 44 | 14 |
| Mirtazapine | Mirtazapine | 44 | 15 |
| Carvedilol | Carvedilol | 43 | 15 |
| Lorazepam | Lorazepam | 43 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | 12 |
| Torsemide | Torsemide | 42 | 18 |
| Valacyclovir | Valacyclovir Hcl | 42 | 22 |
| Ozempic | Semaglutide | 39 | suppressed |
| Valsartan | Valsartan | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 11 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 38 | 11 |
| Ondansetron Odt | Ondansetron | 38 | 19 |
| Pregabalin | Pregabalin | 38 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 37 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 23 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 34 | suppressed |
| Prednisone | Prednisone | 34 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 11 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | 11 |
| Glipizide Er | Glipizide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Glipizide | Glipizide | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Minoxidil | Minoxidil | 23 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Diazepam | Diazepam | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | 11 |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Zolmitriptan | Zolmitriptan | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | 13 |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.78 · 24 records | PFIZER INC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error